FDA Genetic Array Submissions Guidance Dovetails With NCCLS Effort
This article was originally published in The Gray Sheet
Executive Summary
FDA's guidance on "Pharmacogenetic Tests and Genetic Tests for Heritable Markers," to be issued by year-end, will exclude gene expression arrays, according to the agency
You may also be interested in...
Industry Seeks Changes In FDA Drug/Diagnostic Co-Development Model
FDA should employ more realistic timelines for drug/diagnostic co-development when it crafts draft guidance on the topic, stakeholders argue in written comments to the agency
Industry Seeks Changes In FDA Drug/Diagnostic Co-Development Model
FDA should employ more realistic timelines for drug/diagnostic co-development when it crafts draft guidance on the topic, stakeholders argue in written comments to the agency
ASR Guidance Development May Be Supported By AdvaMed FAQ Document
AdvaMed plans to revise a set of frequently asked questions related to analyte specific reagents that could be used as a starting point for an FDA guidance document, following a recent meeting with the agency